AbbVie (ABBV) and Xilio Therapeutics (XLO) said Wednesday they are collaborating and have signed an option-to-license agreement to develop tumor-activated, antibody-based immunotherapies, including masked T-cell engagers.
The companies said they will combine Xilio's tumor-activation technology with AbbVie's research and development efforts in oncology.
As part of the deal, Xilio will receive $52 million upfront, including a $10 million equity investment, the companies said, adding that Xilio could also earn up to $2.1 billion in milestone payments plus royalties.
Shares of Xilio Therapeutics soared 120% in recent premarket activity, while AbbVie shares were up 0.1%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.